Fr1da: General-population infant/child islet-autoantibody screening (Bavaria)
What this study tests
Bavarian population screening for islet autoantibodies showed that screening young children in primary care is feasible. The observational cohort had a low frequency of DKA among children diagnosed through screening and follow-up, but it was not a randomized test of DKA prevention.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2024-12-17.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Open to children in Bavaria (and, in later expansions, other regions) brought to participating primary-care pediatricians, with written consent from a parent. The core screening was offered to young children roughly aged 2-5 during well-child visits; the program has since broadened to additional ages. Children do not need any family history of diabetes — this is general-population screening, not just for relatives. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- Of 90,632 children screened in the first analysis, 0.31% had presymptomatic type 1 diabetes (two or more islet autoantibodies). Capillary finger-prick sampling worked in over 99% of children, showing routine-care screening is feasible. Among 62 children diagnosed with clinical diabetes at initial screening or during follow-up, 2 had mild or moderate diabetic ketoacidosis. This observational cohort cannot by itself establish how much screening reduces DKA compared with no screening. The 3-year risk of progressing to clinical (stage 3) diabetes among those with early-stage disease was about 25%. Parental stress rose briefly at diagnosis but fell over 12 months of follow-up.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: European Union. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Presence of multiple islet autoantibodies. DKA frequency and parental psychological stress were secondary outcomes in the published screening cohort.
The full picture
What Fr1da is, and why it matters
Type 1 diabetes does not start the day a child gets sick. Years earlier, the immune system begins attacking the insulin-making cells, and this leaves a fingerprint in the blood: "islet autoantibodies." When a child has two or more of these autoantibodies, they have early-stage type 1 diabetes and carry a high risk of progressing to need insulin over time — though how fast, and for any given child whether, varies.1
Fr1da is a public-health program in Bavaria, Germany, that tests young children for these autoantibodies during ordinary pediatrician visits, long before symptoms appear.2 The goal is to catch the disease early so families can prepare, avoid a dangerous crisis at diagnosis, and become eligible for prevention trials.2
Who it's for and how it's designed
This is general-population screening — any child can take part, regardless of family history.2 It is an observational program (no drug is tested in the screening itself), run by the Helmholtz Zentrum München diabetes-research institute and led by Prof. Anette-Gabriele Ziegler.3 The core test was offered to children roughly aged 2-5 at routine well-child visits, using a simple finger-prick (capillary) blood sample; the program has since expanded to more ages and regions.23 Children found to have multiple autoantibodies are invited for metabolic staging, diabetes education, and ongoing monitoring.1 Hundreds of thousands of children have been screened, and the program is still recruiting, with follow-up planned to continue for years.3
Key results
In the first major analysis, 90,632 children were screened, and 0.31% had presymptomatic type 1 diabetes.1 The finger-prick approach worked in more than 99% of children, showing that population screening within routine care is genuinely feasible.2 Crucially, among children who went on to clinical diabetes, 2 of the 62 children with stage 3 disease at screening or during follow-up had mild or moderate diabetic ketoacidosis (DKA). This was an observational cohort, so comparisons with unscreened children cannot isolate the causal effect of screening.1 Among those with early-stage disease, the 3-year risk of progressing to clinical diabetes was about 25%.1 Parents' stress rose briefly after diagnosis but declined over the following year.1 Later work refined the staging, identifying substages with very different 2-year progression risks.4
What it means and what's next
Fr1da demonstrated that population screening can be delivered through primary care and observed infrequent DKA with education and monitoring. It did not randomize children to screening versus no screening.1 It now serves as a blueprint for national and international screening efforts and as a pipeline of early-stage children who may benefit from disease-delaying immune therapies.4
Sources
- [1]
- [2]Raab J, et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. *BMJ Open* (2016) · Peer-reviewed study
Raab J, et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open (2016).
Raab J, et al. Design and initial results of the Fr1da study (feasibility and capillary sampling). BMJ Open (2016).
- [3]Fr1da: Early Diagnosis and Care of Type 1 Diabetes. *ClinicalTrials.gov* NCT04039945 (accessed 2026) · Trial registry
Fr1da: Early Diagnosis and Care of Type 1 Diabetes. ClinicalTrials.gov NCT04039945 (accessed 2026).
- [4]Weiss A, et al. Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. *Diabetologia* (2022) · Peer-reviewed study
Weiss A, et al. Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. Diabetologia (2022).